查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1845696

全球照護現場分子診斷市場規模（按產品/服務、技術、應用、最終用戶、區域範圍和預測）

Global Point Of Care Molecular Diagnostics Market Size By Product And Service, By Technology, By Application, By End User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

照護現場分子診斷的市場規模與預測

預計 2024 年照護現場分子診斷市場規模將達到 36.1 億美元，到 2032 年將達到 83.5 億美元，2026 年至 2032 年的複合年成長率為 12.2%。

即時診斷 (POC) 分子診斷市場涵蓋在患者所在地或附近檢測和分析遺傳物質（DNA 或 RNA）的診斷測試的開發、生產和銷售。與需要將樣本送到集中式設施進行分析的傳統實驗室分子測試不同，POC 分子診斷通常可在幾分鐘內快速提供結果，使醫療保健提供者能夠及時做出明智的臨床決策。該市場的發展得益於將複雜的測試流程微型化到緊湊便攜的設備中，並利用聚合酵素鏈鎖反應(PCR) 和等溫擴增等技術。其主要目標是改善醫療保健的可近性，縮短週轉時間，並加速治療啟動，尤其是在感染疾病、遺傳性疾病和腫瘤學領域。

POC分子診斷市場的意義在於它能夠彌合傳統實驗室檢測與患者緊急需求之間的差距。其應用範圍從急診和醫生辦公室到遠距診所甚至居家醫療。該市場的主要驅動力包括感染疾病爆發、對快速和分散診斷解決方案日益成長的需求，以及將多個測試步驟整合到一個易於使用的平台的微流體和晶片實驗室技術的進步。 COVID-19大流行起到了重要的催化劑作用，凸顯了快速、準確和可訪問的分子檢測在疾病監測和控制中的關鍵作用。因此，隨著人工智慧和機器學習等技術的整合越來越受到關注，以進一步提高診斷的準確性和效率，市場有望實現顯著成長。

全球 POC 分子診斷市場促進因素

受重塑醫療保健格局的許多因素共同推動，照護現場(POC) 分子診斷市場正經歷強勁成長。從公共衛生危機到技術突破，這些因素正推動該產業朝著更分散、便利和以患者為中心的模式發展。以下分析將探討推動該市場發展的關鍵因素，並重點介紹它們對臨床和商業領域的影響。

感染疾病發生率上升：全球感染疾病發生率不斷上升，包括流感、結核病和愛滋病毒等眾所周知的病原體，以及新出現的威脅，是 POC 分子診斷市場的主要驅動力。傳統的實驗室診斷通常需要很長的周轉時間，可能會延誤治療並導致高傳染性疾病的傳播。 POC 分子診斷提供了一個至關重要的解決方案，可在患者門口提供快速且準確的結果，從而實現即時的臨床決策和有效的感染控制。 COVID-19 大流行起到了強大的催化劑作用，證明了快速 POC 檢測在控制疫情和進行廣泛監測方面發揮著至關重要的作用。人們對感染疾病診斷的認知和投資不斷成長，對可攜式、方便用戶使用的分子檢測平台產生了持續的需求。

對快速精準診斷的需求日益成長：在現代醫療保健領域，時間至關重要，對快速精準診斷的需求是不可動搖的市場驅動力。醫療保健提供者越來越重視能夠提供快速、可靠結果並支援即時臨床決策的診斷工具。從鏈球菌咽頭炎到敗血症，快速診斷可以顯著改善患者預後，並減少不必要的抗生素處方。即時分子診斷能夠在幾分鐘內提供實驗室層級的結果，直接滿足了這項需求。更有效率的醫療工作流程、更短的住院時間和更低的醫療總成本，進一步推動了這一趨勢，因為早期準確的診斷可以預防疾病進展，並避免日後更複雜、更昂貴的治療。

分子診斷技術的進步：分子診斷技術的持續進步正在顯著推動市場發展。複雜實驗室設備的小型化，加上微流體和奈米技術的突破，催生了高度緊湊、便攜且方便用戶使用的設備。這些技術創新使得將多個檢測步驟整合到單一「晶片實驗室」平台成為可能。此外，人工智慧 (AI) 和機器學習的結合，透過改善數據分析、減少假陽性並提供結果的自動化解讀，提升了這些設備的性能和易用性。這些技術突破使先進的分子檢測能夠應用於更廣泛的醫療機構和用戶，從鄉村診所到醫生診所，從而拓寬了市場基礎。

醫療服務日益去中心化：醫療服務去中心化的根本性轉變是即時診斷（POC）分子診斷市場發展的強大驅動力。隨著醫療模式不斷發展，更加注重患者的便利性和可近性，對可在傳統中心實驗室之外使用的診斷解決方案的需求日益成長。這包括門診護理、居家醫療和遠距醫療的普及。可攜式、易於使用的分子診斷設備非常適合這些環境，使醫療保健提供者能夠在一次就診中提供從諮詢到診斷再到治療的全方位護理。這一趨勢在地域廣闊和服務不足的社區尤其顯著，因為在這些地區，集中檢測的後勤挑戰曾是及時醫療的一大障礙。

早期疾病檢測需求：早期疾病檢測需求是一個關鍵促進因素，因為它直接關係到治療效果的改善和患者的整體幸福感。無論是感染疾病、遺傳性疾病或癌症，早期診斷都可能意味著輕微干預和危及生命的疾病之間的差異。即時診斷 (POC) 分子診斷透過提供快速且準確的篩檢和檢測能力，在這一領域發揮關鍵作用。例如，快速的即時診斷可以檢測遺傳易感性或病毒感染，從而製定快速、有針對性的治療方案，最大限度地減少疾病對患者的影響。在醫療專業人士和消費者的支持下，對預防性和主動性醫療保健的日益重視正在推動這些技術在各種臨床應用中的應用。

限制全球POC分子診斷市場的因素

儘管照護現場(POC) 分子診斷市場擁有巨大的潛力，有望改變醫療保健產業，但它仍面臨許多重大限制因素，阻礙其廣泛應用。從經濟障礙到物流複雜性，再到監管障礙，必須應對這些挑戰，才能充分發揮市場潛力，尤其是在全球環境日益多樣化的今天。

分子診斷設備高成本：分子診斷設備成本高是一大限制因素，尤其是在醫療預算有限的中低收入地區。開發這些系統所需的先進技術、複雜組件和嚴謹的研發，導致其製造和最終採購價格高。這使得新興經濟體的小型診所、醫院和公共衛生系統難以投資和採用這些工具。不僅初始資本支出，專用檢測試劑等耗材的經常性成本也進一步加重了經濟負擔，阻礙了其廣泛應用。因此，市場往往集中在資源充足的醫療體系中，而許多服務匱乏的人仍然無法獲得這些快速診斷服務。

技術專長有限：成功操作分子診斷設備需要專業訓練和技術專長，這在偏遠、資源有限的地區可能是一項重大挑戰。儘管該行業正在朝著更方便用戶使用、自動化的平台邁進，但許多系統仍然需要細緻的樣品製備、精確的試劑處理以及謹慎的結果解讀，以避免錯誤。在許多發展中國家，甚至在已開發國家的一些分散環境中，缺乏經過充分培訓的人員會導致檢測結果不準確、營運效率低下以及對技術缺乏信心。這種技能差距需要持續投資培訓和教育項目，這可能會給醫療保健提供者帶來額外的成本和物流挑戰。

嚴格的監管要求：開發新型分子診斷技術是一個複雜的過程，需要遵守嚴格的監管要求，這可能會嚴重拖延其市場准入和商業化進程。美國（FDA）和歐洲（MDR）等主要市場的監管機構擁有嚴格且通常冗長的核准流程，以確保新設備的安全性和有效性。臨床試驗、檢驗研究和大量文件的投入給製造商，尤其是創新中小企業帶來了沉重的負擔。此外，在不同國家/地區應對不同法律規範的複雜性也為全球市場擴張帶來了挑戰，減緩了新型診斷解決方案到達最需要它們的最終用戶的速度。

對準確性和靈敏度的擔憂：雖然即時檢測 (POC) 分子診斷通常被認為具有高度準確性，但在實際環境中對其準確性和靈敏度的擔憂仍然是一個障礙。檢測性能的差異可能源自於使用者錯誤、檢體處理不當以及極端環境條件（例如溫度和濕度）等因素。這些問題可能導致假陽性和假陰性，從而對患者照護、公共衛生和消費者信心造成潛在的嚴重後果。與條件嚴格控制且品質保證協議健全的傳統實驗室環境不同，POC 檢測是分散式的，因此更容易受到這些變數的影響。克服這一限制需要不斷改進穩健的技術，並在照護端實施嚴格的品管和品質保證措施。

開發中地區基礎設施不足：在許多開發中地區，缺乏充足的醫療保健基礎設施是即時檢測（POC​​）分子診斷應用的主要障礙。許多設備需要穩定的電源、可靠的網路連接以進行資料傳輸，以及受控的儲存環境以確保試劑和套件的正常運作。遺憾的是，這些基本要求在農村診所和偏遠地區往往無法滿足。缺乏穩定的電網、缺乏敏感試劑的冷藏保管以及供應鏈物流不足，阻礙了這些技術的採用和有效使用，限制了它們在這些地區滿足關鍵公共衛生需求的潛力。

目錄

第1章 引言

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第2章調查方法

  • 資料探勘
  • 二次調查
  • 初步調查
  • 專家建議
  • 品質檢查
  • 最終審核
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程
  • 資訊服務類型

第3章執行摘要

  • 全球POC分子診斷市場概況
  • 全球即時分子診斷市場的估計與預測
  • 全球即時分子診斷市場的生態圖譜
  • 競爭分析漏斗圖
  • 全球即時診斷分子診斷市場絕對商機
  • 全球即時分子診斷市場吸引力分析（按地區）
  • 全球即時分子診斷市場吸引力分析（按產品和服務）
  • 全球即時分子診斷市場吸引力分析（按技術）
  • 全球 POC 分子診斷市場吸引力分析（按應用）
  • 全球照護現場分子診斷市場吸引力分析（按最終用戶）
  • 全球分子診斷市場區域分析
  • 全球照護現場分子診斷市場（按產品和服務分類）
  • 全球POC分子診斷市場（按技術）
  • 全球 POC 分子診斷市場（按應用）
  • 全球POC分子診斷市場（按地區）
  • 未來市場機遇

第4章 市場展望

  • 全球照護現場分子診斷市場
  • 全球POC分子診斷市場展望
  • 市場促進因素
  • 市場限制
  • 市場趨勢
  • 市場機遇
  • 波特五力分析
    • 新進入者的威脅
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 現有競爭對手之間的敵意
  • 價值鏈分析
  • 定價分析
  • 宏觀經濟分析

第5章 產品/服務市場

  • 概述
  • 檢測套組
  • 儀器/分析儀
  • 軟體和服務

第6章 按技術分類的市場

  • 概述
  • RT PCR
  • INAAT

第7章 按應用分類的市場

  • 概述
  • 癌症
  • 感染疾病
  • 血液學
  • 內分泌學

第 8 章 最終用戶市場

  • 概述
  • 醫院和診所
  • 診斷中心

第9章 區域市場

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

第10章 競爭格局

  • 概述
  • 主要發展策略
  • 公司的地理分佈
  • 王牌矩陣
    • 積極的
    • 前線
    • 新興
    • 創新者

第11章 公司簡介

  • OVERVIEW
  • ABBOTT LABORATORIES INC.
  • ROCHE DIAGNOSTICS
  • BIOMERIEUX SA
  • DANAHER CORPORATION
  • CEPHEID
  • QIAGEN NV
  • THERMO FISHER SCIENTIFIC INC.
  • HOLOGIC INC.
  • BIO RAD LABORATORIES INC.
  • BECTON
  • DICKINSON AND COMPANY
  • GENMARK DIAGNOSTICS INC.
  • MERIDIAN BIOSCIENCE INC.
  • MESA BIOTECH INC.
  • BIOCARTIS GROUP NV
  • QUANTUMDX GROUP LIMITED
Product Code: 11910

Point Of Care Molecular Diagnostics Market Size And Forecast

Point Of Care Molecular Diagnostics Market size was valued at USD 3.61 Billion in 2024 and is projected to reach USD 8.35 Billion by 2032, growing at a CAGR of 12.2% from 2026 to 2032.

The Point of Care (POC) Molecular Diagnostics Market encompasses the development, production, and sale of diagnostic tests that detect and analyze genetic material (DNA or RNA) at or near a patient's location. Unlike traditional lab based molecular tests that require samples to be sent to a centralized facility for analysis, POC molecular diagnostics provide rapid results, often within minutes, enabling healthcare providers to make timely and informed clinical decisions. This market is driven by the miniaturization of complex lab processes onto compact, portable devices, often leveraging technologies like Polymerase Chain Reaction (PCR) and isothermal amplification. The primary objective is to improve healthcare accessibility, reduce turnaround times, and facilitate faster treatment initiation, particularly for infectious disease, genetic disorders, and oncology.

The significance of the POC Molecular Diagnostics Market lies in its ability to bridge the gap between traditional laboratory testing and immediate patient needs. Its applications are widespread, from emergency departments and physician's offices to remote clinics and even home care settings. Key drivers for this market include the increasing prevalence of infectious diseases, a growing need for rapid and decentralized diagnostic solutions, and advancements in microfluidic and lab on a chip technologies that integrate multiple testing steps into a single, user friendly platform. The COVID 19 pandemic served as a major catalyst, highlighting the critical role of rapid, accurate, and accessible molecular testing in disease surveillance and control. As a result, the market is poised for significant growth, with a growing focus on integrating technologies like AI and machine learning to further enhance diagnostic accuracy and efficiency.

Global Point Of Care Molecular Diagnostics Market Drivers

The Point of Care (POC) Molecular Diagnostics market is experiencing robust growth, driven by a convergence of factors that are reshaping the healthcare landscape. From public health crises to technological breakthroughs, these drivers are collectively pushing the industry toward a more decentralized, accessible, and patient centric model. The following analysis explores the key forces propelling this market forward, highlighting their impact on both the clinical and commercial spheres.

Rising Prevalence of Infectious Diseases: The increasing global incidence of infectious diseases, including well known pathogens like influenza, tuberculosis, and HIV, as well as emerging threats, is a primary driver for the Point of Care Molecular Diagnostics market. Traditional lab based diagnostics often have a long turnaround time, which can delay treatment and contribute to the spread of highly contagious illnesses. POC molecular diagnostics offer a crucial solution by providing rapid and accurate results at or near the patient, enabling immediate clinical decisions and effective infection control. The COVID 19 pandemic served as a powerful catalyst, demonstrating the indispensable role of rapid POC testing in managing outbreaks and conducting widespread surveillance. This heightened awareness and investment in infectious disease diagnostics have created a sustained demand for portable, user friendly molecular testing platforms.

Growing Demand for Rapid and Accurate Diagnostics: In modern healthcare, time is a critical factor, and the demand for rapid and accurate diagnostics has become a non negotiable market driver. Healthcare providers are increasingly prioritizing diagnostic tools that can deliver fast, reliable results to enable immediate clinical decision making. For conditions ranging from strep throat to sepsis, a speedy diagnosis can dramatically improve patient outcomes and reduce the need for unnecessary antibiotic prescriptions. POC molecular diagnostics, with their ability to provide lab quality results in minutes, directly address this need. This trend is further supported by the push for more efficient healthcare workflows, shorter hospital stays, and a reduction in the overall cost of care, as early and accurate diagnosis can prevent the progression of diseases and avoid more complex and expensive treatments later on.

Advancements in Molecular Diagnostic Technologies: The market is being significantly propelled by continuous advancements in molecular diagnostic technologies. Miniaturization of complex lab equipment, coupled with breakthroughs in microfluidics and nanotechnology, has led to the creation of highly compact, portable, and user friendly devices. These innovations allow for the integration of multiple testing steps onto a single "lab on a chip" platform. Furthermore, the incorporation of artificial intelligence (AI) and machine learning is enhancing the performance and usability of these devices by improving data analysis, reducing false positives, and providing automated interpretation of results. These technological leaps are making sophisticated molecular testing more accessible to a wider range of healthcare settings and users, from rural clinics to physicians' offices, thereby broadening the market's reach.

Increasing Decentralization of Healthcare Services: A fundamental shift towards the decentralization of healthcare services is a powerful driver for the POC molecular diagnostics market. As healthcare models evolve to prioritize patient convenience and accessibility, there is a growing demand for diagnostic solutions that can be used outside of traditional centralized laboratories. This includes the proliferation of outpatient care, home healthcare, and remote clinics. Portable and easy to use molecular diagnostic devices are perfectly suited for these settings, allowing healthcare providers to offer a full spectrum of care, from consultation to diagnosis and treatment, in a single visit. This trend is particularly impactful in regions with vast geographic areas or underserved communities, where the logistical challenges of centralized testing have historically been a barrier to timely care.

Need for Early Disease Detection: The need for early disease detection is a critical driver, as it is directly linked to better treatment outcomes and overall patient well being. Whether for infectious diseases, genetic disorders, or cancer, diagnosing a condition in its early stages can be the difference between a minor intervention and a life threatening illness. Point of care molecular diagnostics play a vital role in this by providing rapid, accurate screening and detection capabilities. For example, a quick POC test for a genetic predisposition or a viral infection can lead to a prompt and targeted therapeutic plan, minimizing the disease's impact on the patient. This emphasis on proactive and preventative healthcare, championed by both medical professionals and consumers, is fueling the adoption of these technologies across various clinical applications.

Global Point Of Care Molecular Diagnostics Market Restraints

Despite its immense potential to transform healthcare, the Point of Care (POC) Molecular Diagnostics market faces several significant restraints that hinder its widespread adoption. These challenges, ranging from economic hurdles to logistical complexities and regulatory obstacles, must be addressed for the market to reach its full potential, particularly in diverse global settings.

High Cost of Molecular Diagnostic Devices: The high cost of molecular diagnostic devices is a major restraint, particularly in low and middle income regions where healthcare budgets are limited. The advanced technology, complex components, and rigorous R&D required to develop these systems lead to high manufacturing and final purchase prices. This makes it difficult for smaller clinics, physicians' offices, and public health systems in developing economies to invest in and adopt these tools. Beyond the initial capital outlay, the recurring cost of consumables, such as specialized assays and reagents, further adds to the financial burden, creating a barrier to widespread implementation. The market is therefore often concentrated in well funded healthcare systems, while many underserved populations remain without access to these rapid diagnostic capabilities.

Limited Technical Expertise: The successful operation of some molecular diagnostic devices requires specialized training and technical expertise, which can be a significant challenge in resource limited and remote settings. While the industry is moving towards more user friendly, automated platforms, many systems still require meticulous sample preparation, precise handling of reagents, and careful interpretation of results to avoid errors. The lack of adequately trained personnel in many developing regions, and even in some decentralized settings in developed countries, can lead to inaccurate test results, operational inefficiencies, and a lack of trust in the technology. This skill gap necessitates ongoing investment in training and education programs, which can be an additional cost and logistical challenge for healthcare providers.

Stringent Regulatory Requirements: The development of new molecular diagnostic products is a complex process, subject to stringent regulatory requirements that can significantly delay market entry and commercialization. Regulatory bodies in key markets like the United States (FDA) and Europe (MDR) have rigorous and often lengthy approval processes to ensure the safety and efficacy of new devices. This creates a significant burden for manufacturers, particularly smaller innovative companies, as it requires substantial investment in clinical trials, validation studies, and extensive documentation. The complexity of navigating different regulatory frameworks across various countries also poses a challenge for global market expansion, slowing down the pace at which novel diagnostic solutions can reach the end users who need them most.

Concerns Over Accuracy and Sensitivity: While POC molecular diagnostics are generally considered highly accurate, concerns over their accuracy and sensitivity in real world settings remain a restraint. Variability in test performance can arise from factors such as user error, improper sample handling, and extreme environmental conditions (e.g., temperature and humidity). These issues can lead to false positives or false negatives, which can have severe consequences for patient care, public health, and user trust. Unlike traditional laboratory settings where conditions are tightly controlled and quality assurance protocols are robust, the decentralized nature of POC testing makes it more susceptible to these variables. Overcoming this restraint requires continuous improvement in technology to enhance robustness and the implementation of rigorous quality control and quality assurance measures at the point of care.

Inadequate Infrastructure in Developing Regions: The lack of proper healthcare infrastructure in many developing regions is a major barrier to the adoption of POC molecular diagnostics. The successful operation of many devices requires a stable power supply, reliable internet connectivity for data transfer, and controlled storage environments for reagents and kits. Unfortunately, these basic requirements are often not met in rural clinics and remote areas. The absence of a stable electrical grid, a lack of refrigerated storage for sensitive reagents, and poor supply chain logistics can hinder the implementation and effective use of these technologies, limiting their potential to address critical public health needs in these regions.

Global Point Of Care Molecular Diagnostics Market Segmentation Analysis

The Point Of Care Molecular Diagnostics Market is segmented based on Product & Service, Technology, Application, End User, and Geography.

Point Of Care Molecular Diagnostics Market, By Product & Service

Assays & Kits

Instruments & Analyzers

Software & Services

Based on Product & Service, the Point Of Care Molecular Diagnostics Market is segmented into Assays & Kits, Instruments & Analyzers, and Software & Services. At VMR, we observe that the Assays & Kits segment is the dominant subsegment, holding the largest market share and driving the market's recurring revenue. Its dominance stems from its consumable nature; for every test performed on a POC molecular instrument, a specific assay or kit is required. This makes the segment's revenue stream consistent and directly tied to the utilization of the installed base of instruments. The high volume of infectious disease testing, particularly for respiratory illnesses and STIs, further propels this segment. According to recent reports, Assays & Kits accounted for a majority of the market share, with some data indicating it comprised over 50% of the market in 2024. This market is also characterized by continuous innovation, with companies constantly developing new and improved assays that are more sensitive, specific, and can detect multiple pathogens from a single sample (multiplexing), thus ensuring its ongoing dominance.

The Instruments & Analyzers subsegment is the second most dominant, playing a crucial role by providing the hardware necessary for molecular testing. While this segment has a higher average selling price and is not a recurring purchase like kits, its growth is driven by the increasing demand for compact, portable, and automated devices that can be used in decentralized settings. The market for instruments is highly competitive, with a focus on developing user friendly platforms that require minimal training. As the installed base of these instruments grows, it, in turn, fuels the demand for the Assays & Kits segment, creating a symbiotic relationship.

The Software & Services subsegment plays a supporting role by enhancing the functionality and usability of the hardware and kits. While it currently holds the smallest market share, its future potential is significant. This segment includes data management solutions, connectivity services for remote monitoring and result reporting, and maintenance services. The increasing digitalization of healthcare and the need for seamless data integration are poised to drive the growth of this subsegment, as it adds value beyond the physical products.

Point Of Care Molecular Diagnostics Market, By Technology

RT PCR

INAAT

Based on Technology, the Point Of Care Molecular Diagnostics Market is segmented into RT PCR and INAAT. At VMR, we observe that Real Time PCR (RT PCR) is the dominant subsegment, a position it maintains due to its unparalleled sensitivity, specificity, and quantitative accuracy, which are considered the gold standard in molecular diagnostics. The widespread adoption of RT PCR was significantly accelerated by the COVID 19 pandemic, where it became the primary method for virus detection, leading to a massive increase in its use in hospitals and decentralized settings globally. Even post pandemic, its extensive clinical utility continues in infectious disease testing for influenza, HIV, and various STIs. According to industry data, the RT PCR segment held approximately 45% of the point of care molecular diagnostics market in 2024, a testament to its reliability. The ongoing miniaturization and development of portable RT PCR systems have further solidified its dominance, enabling high quality, lab standard testing at or near the patient's location, particularly in North America, which has a highly advanced healthcare infrastructure and significant R&D investments.

The Isothermal Nucleic Acid Amplification Technology (INAAT) subsegment is the second most dominant, with a crucial role as a faster, more accessible, and often more cost effective alternative to RT PCR. Unlike RT PCR, INAAT does not require sophisticated thermal cycling equipment, allowing for simpler, battery powered devices suitable for use in resource limited settings and for at home testing. Its growth is driven by the demand for rapid, on the spot results, with technologies like Loop mediated Isothermal Amplification (LAMP) gaining significant traction. While INAAT is poised for a higher growth rate over the forecast period due to its operational simplicity and lower cost, its current market share is smaller, as it is still gaining trust and a wider range of applications compared to the established RT PCR.

Point Of Care Molecular Diagnostics Market, By Application

Cancer

Infectious Diseases

Hematology

Endocrinology

Based on Application, the Point Of Care Molecular Diagnostics Market is segmented into Cancer, Infectious Diseases, Hematology, and Endocrinology. At VMR, we observe that the Infectious Diseases subsegment is overwhelmingly dominant, holding the largest market share and serving as the primary growth engine for the overall market. This dominance is driven by the urgent need for rapid and accurate diagnosis of infectious pathogens, particularly in emergency settings, decentralized clinics, and remote locations. The segment's growth was significantly accelerated by the COVID 19 pandemic, which underscored the critical role of accessible and quick testing for effective disease management and public health surveillance. According to our analysis, the Infectious Diseases segment holds a market share of approximately 31.5% and is expected to continue its robust growth trajectory. The widespread adoption of highly accurate technologies like RT PCR for rapid testing of respiratory infections (e.g., COVID 19, influenza), sexually transmitted infections, and hospital acquired infections is a key driver. This segment is heavily relied upon by hospitals, clinics, and even at home users for timely diagnosis and to enable prompt treatment and infection control.

The Cancer subsegment is the second most dominant, and while it holds a smaller share, it is poised for the most significant future growth. Its role is becoming increasingly critical with the shift towards personalized medicine and the growing demand for early and precise cancer detection. Point of care molecular diagnostics in oncology are used to identify specific genetic mutations and biomarkers from a small sample, guiding treatment selection and monitoring therapy response. The growth in this segment is fueled by technological advancements like liquid biopsy, which provides a non invasive method for cancer detection, and the integration of AI to analyze complex genomic data. This segment is projected to grow at a high CAGR, with some forecasts placing it at over 12% through 2030, reflecting its importance in modern cancer care.

The remaining subsegments, Hematology and Endocrinology, play a supporting role, catering to more specialized and niche applications. The Hematology segment is used for rapid analysis of blood related disorders, while the Endocrinology segment focuses on hormone related conditions. While their market share is smaller, the ability to perform these tests at the point of care provides significant benefits in terms of reducing diagnostic delays and improving patient management, indicating their potential for targeted growth as the technology becomes more widespread and cost effective.

Point Of Care Molecular Diagnostics Market, By End User

Hospitals & Clinics

Diagnostic Centers

Based on End User, the Point Of Care Molecular Diagnostics Market is segmented into Hospitals & Clinics and Diagnostic Centers. At VMR, we observe that the Hospitals & Clinics segment is the dominant subsegment, commanding the largest market share and driving significant adoption of POC molecular diagnostics. This dominance is primarily due to the high volume of patients they serve and their critical need for rapid, accurate diagnostic solutions in emergency, critical care, and outpatient settings. The adoption is further fueled by the increasing prevalence of infectious diseases and the demand for timely clinical decisions to improve patient outcomes and streamline workflows. Data from various market reports suggests that hospitals and clinics account for over 40% of the market share, highlighting their role as the primary end users. The trend towards decentralizing testing from large, centralized labs to smaller, on site hospital or clinic labs is a major driver, as it reduces turnaround times, shortens hospital stays, and improves overall efficiency. The ability of POC molecular platforms to provide laboratory quality results with minimal technical expertise makes them a perfect fit for these settings.

The Diagnostic Centers segment is the second most dominant subsegment, playing a crucial role in providing specialized and often high volume testing services. While not always at the "point of care" in the same way as a hospital emergency room, these centers leverage molecular diagnostic technologies to offer a broad range of tests, from infectious disease panels to genetic screenings. Their growth is driven by the increasing demand for specialized testing services and the rising number of patients seeking preventative care and targeted diagnostics. Diagnostic centers often act as a bridge between physicians' offices and centralized labs, providing a more localized and convenient option for patients.

While not explicitly a subsegment in the provided list, the Homecare setting is an emerging end user with significant future potential. This segment, though currently holding a smaller share, is expected to grow rapidly due to the rising trend of at home testing, which offers convenience and accessibility. The development of user friendly, portable devices for at home use, such as those for COVID 19 or flu testing, is expanding this niche and will likely contribute more to the market's revenue in the coming years.

Point Of Care Molecular Diagnostics Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

The Point of Care (POC) Molecular Diagnostics market is a globally expanding sector, with significant regional variations in adoption rates, growth drivers, and market maturity. While North America and Europe currently dominate the market due to their advanced healthcare infrastructure and robust regulatory frameworks, the Asia Pacific region is emerging as a high growth hub. Each region presents a unique set of opportunities and challenges shaped by economic development, disease burden, and healthcare policies.

United States Point Of Care Molecular Diagnostics Market

The United States holds the dominant position in the global POC molecular diagnostics market, accounting for a substantial share of the total revenue. This leadership is driven by several key factors, including a highly advanced healthcare infrastructure, significant investments in research and development, and the widespread adoption of molecular diagnostics in hospitals, clinics, and decentralized laboratories. A major trend in the U.S. is the growing demand for at home testing and the integration of POC devices with telehealth services, which enhances patient convenience and accessibility. The market is also fueled by the high prevalence of infectious diseases and chronic conditions, coupled with a strong emphasis on rapid and accurate diagnosis to improve patient outcomes.

Europe Point Of Care Molecular Diagnostics Market

Europe represents a mature and significant market for POC molecular diagnostics. The market's growth is propelled by the increasing prevalence of infectious diseases, a rising burden of chronic and genetic disorders, and a strong push for healthcare decentralization to improve efficiency and reduce costs. Countries like Germany and the UK are key contributors, benefiting from advanced healthcare systems and a focus on technological advancements. The regulatory landscape in Europe, while stringent, provides a stable environment for innovation. A key trend is the development of user friendly, portable devices that facilitate on site detection of a broad range of infectious diseases, with PCR based technologies dominating the market due to their high accuracy and rapid results.

Asia Pacific Point Of Care Molecular Diagnostics Market

The Asia Pacific region is poised to be the fastest growing market for POC molecular diagnostics. This rapid growth is driven by several factors, including improving healthcare infrastructure, a large and growing population, and increasing government initiatives to combat infectious diseases. Countries such as China, India, and Japan are at the forefront of this growth, with rising healthcare spending and a growing awareness of the benefits of early diagnosis. While cost remains a challenge, the region's increasing demand for accessible and affordable diagnostic solutions is pushing for localized manufacturing and the adoption of low cost, high volume testing platforms. The convergence of a high disease burden and a strong push for healthcare modernization makes this a prime region for future market expansion.

Latin America Point Of Care Molecular Diagnostics Market

The Latin America POC molecular diagnostics market is a developing sector with considerable growth potential. The market is driven by the high prevalence of infectious diseases, a growing awareness of healthcare, and government initiatives aimed at improving public health. Brazil and Mexico are key players in the region, benefiting from a large population base and increased healthcare expenditure. The adoption of POC diagnostics is particularly critical in rural and underserved areas, where access to centralized laboratories is limited. A key trend is the focus on rapid diagnostic tests for endemic infectious diseases like dengue, Zika, and HIV, which aids in disease surveillance and management.

Middle East & Africa Point Of Care Molecular Diagnostics Market

The Middle East and Africa (MEA) region presents a nascent but rapidly evolving market for POC molecular diagnostics. The market is driven by a high burden of infectious diseases, including HIV, tuberculosis, and malaria, and a growing recognition of the need for rapid diagnostic tools to manage outbreaks. Governments in the region, particularly in the GCC countries (e.g., Saudi Arabia and the UAE), are making significant investments in modernizing their healthcare infrastructure. The market is also benefiting from the increasing integration of AI and telemedicine, which helps to bridge the gap in healthcare access. However, challenges such as high costs and limited healthcare spending in certain parts of Africa can act as a restraint on growth, making strategic partnerships and government support crucial for market penetration.

Key Players

  • The major players in the Point Of Care Molecular Diagnostics Market are:
  • Abbott Laboratories Inc.
  • Roche Diagnostics
  • bioMerieux SA
  • Danaher Corporation
  • Cepheid, QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Hologic Inc.
  • Bio Rad Laboratories Inc.
  • Becton
  • Dickinson and Company
  • GenMark Diagnostics Inc.
  • Meridian Bioscience Inc.
  • Mesa Biotech Inc.
  • Biocartis Group NV
  • QuantuMDx Group Limited
  • Reasons to Purchase this Report
  • Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non economic factors
  • Provision of market value (USD Billion) data for each segment and sub segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in depth analysis of the market of various perspectives through Porter's five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • 6 month post sales analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM UP APPROACH
  • 2.9 TOP DOWN APPROACH
  • 2.10 RESEARCH FLOW
  • 2.11 DATA SERVICE TYPES

3 EXECUTIVE SUMMARY

  • 3.1 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
  • 3.2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ESTIMATES AND FORECAST (USD BILLION)
  • 3.3 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ECOLOGY MAPPING
  • 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • 3.5 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ABSOLUTE MARKET OPPORTUNITY
  • 3.6 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • 3.7 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT & SERVICE
  • 3.8 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY
  • 3.9 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
  • 3.10 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY END USER
  • 3.11 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.12 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • 3.13 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • 3.14 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • 3.15 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY (USD BILLION)
  • 3.16 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

  • 4.1 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET EVOLUTION
  • 4.2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OUTLOOK
  • 4.3 MARKET DRIVERS
  • 4.4 MARKET RESTRAINTS
  • 4.5 MARKET TRENDS
  • 4.6 MARKET OPPORTUNITY
  • 4.7 PORTERS FIVE FORCES ANALYSIS
    • 4.7.1 THREAT OF NEW ENTRANTS
    • 4.7.2 BARGAINING POWER OF SUPPLIERS
    • 4.7.3 BARGAINING POWER OF BUYERS
    • 4.7.4 THREAT OF SUBSTITUTE PRODUCTS
    • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
  • 4.8 VALUE CHAIN ANALYSIS
  • 4.9 PRICING ANALYSIS
  • 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY PRODUCT & SERVICE

  • 5.1 OVERVIEW
  • 5.2 ASSAYS & KITS
  • 5.3 INSTRUMENTS & ANALYZERS
  • 5.4 SOFTWARE & SERVICES

6 MARKET, BY TECHNOLOGY

  • 6.1 OVERVIEW
  • 6.2 RT PCR
  • 6.3 INAAT

7 MARKET, BY APPLICATION

  • 7.1 OVERVIEW
  • 7.2 CANCER
  • 7.3 INFECTIOUS DISEASES
  • 7.4 HEMATOLOGY
  • 7.5 ENDOCRINOLOGY

8 MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 HOSPITALS & CLINICS
  • 8.3 DIAGNOSTIC CENTERS

9 MARKET, BY GEOGRAPHY

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 U.S.
    • 9.2.2 CANADA
    • 9.2.3 MEXICO
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 U.K.
    • 9.3.3 FRANCE
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 JAPAN
    • 9.4.3 INDIA
    • 9.4.4 REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 BRAZIL
    • 9.5.2 ARGENTINA
    • 9.5.3 REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST AND AFRICA
    • 9.6.1 UAE
    • 9.6.2 SAUDI ARABIA
    • 9.6.3 SOUTH AFRICA
    • 9.6.4 REST OF MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY DEVELOPMENT STRATEGIES
  • 10.3 COMPANY REGIONAL FOOTPRINT
  • 10.4 ACE MATRIX
    • 10.4.1 ACTIVE
    • 10.4.2 CUTTING EDGE
    • 10.4.3 EMERGING
    • 10.4.4 INNOVATORS

11 COMPANY PROFILES

  • 11.1 OVERVIEW
  • 11.2 ABBOTT LABORATORIES INC.
  • 11.3 ROCHE DIAGNOSTICS
  • 11.4 BIOMERIEUX SA
  • 11.5 DANAHER CORPORATION
  • 11.6 CEPHEID
  • 11.7 QIAGEN N.V.
  • 11.8 THERMO FISHER SCIENTIFIC INC.
  • 11.9 HOLOGIC INC.
  • 11.10 BIO RAD LABORATORIES INC.
  • 11.11 BECTON
  • 11.12 DICKINSON AND COMPANY
  • 11.13 GENMARK DIAGNOSTICS INC.
  • 11.14 MERIDIAN BIOSCIENCE INC.
  • 11.15 MESA BIOTECH INC.
  • 11.16 BIOCARTIS GROUP NV
  • 11.17 QUANTUMDX GROUP LIMITED

LIST OF TABLES AND FIGURES

  • TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 3 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 4 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 5 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 6 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY (USD BILLION)
  • TABLE 7 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
  • TABLE 8 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 9 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 10 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 11 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 12 U.S. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 13 U.S. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 14 U.S. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 15 U.S. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 16 CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 17 CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 18 CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 19 CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 20 MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 21 MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 22 MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 23 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
  • TABLE 24 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 25 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 26 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 27 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 28 GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 29 GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 30 GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 31 GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 32 U.K. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 33 U.K. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 34 U.K. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 35 U.K. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 36 FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 37 FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 38 FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 39 FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 40 ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 41 ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 42 ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 43 ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 44 SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 45 SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 46 SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 47 SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 48 REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 49 REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 50 REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 51 REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 52 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
  • TABLE 53 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 54 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 55 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 56 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 57 CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 58 CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 59 CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 60 CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 61 JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 62 JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 63 JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 64 JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 65 INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 66 INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 67 INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 68 INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 69 REST OF APAC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 70 REST OF APAC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 71 REST OF APAC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 72 REST OF APAC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 73 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
  • TABLE 74 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 75 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 76 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 77 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 78 BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 79 BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 80 BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 81 BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 82 ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 83 ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 84 ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 85 ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 86 REST OF LATAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 87 REST OF LATAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 88 REST OF LATAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 89 REST OF LATAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 90 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
  • TABLE 91 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 92 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 93 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 94 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 95 UAE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 96 UAE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 97 UAE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 98 UAE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 99 SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 100 SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 101 SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 102 SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 103 SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 104 SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 105 SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 106 SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 107 REST OF MEA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
  • TABLE 108 REST OF MEA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
  • TABLE 109 REST OF MEA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
  • TABLE 110 REST OF MEA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
  • TABLE 111 COMPANY REGIONAL FOOTPRINT